Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
105.28
+0.66 (0.63%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Ligand Pharmaceuticals stock have an average target of 144.67, with a low estimate of 135 and a high estimate of 160. The average target predicts an increase of 37.41% from the current stock price of 105.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $143 | Strong Buy | Initiates | $143 | +35.83% | Apr 10, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +28.23% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +51.98% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +35.83% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
Financial Forecast
Revenue This Year
194.66M
from 167.13M
Increased by 16.47%
Revenue Next Year
232.51M
from 194.66M
Increased by 19.44%
EPS This Year
6.21
from -0.22
EPS Next Year
6.79
from 6.21
Increased by 9.20%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 206.4M | 255.3M | 321.2M | ||
| Avg | 194.7M | 232.5M | 278.4M | ||
| Low | 181.3M | 204.3M | 234.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.5% | 31.1% | 38.1% | ||
| Avg | 16.5% | 19.4% | 19.7% | ||
| Low | 8.5% | 4.9% | 1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.53 | 8.01 | 7.78 | ||
| Avg | 6.21 | 6.79 | 7.36 | ||
| Low | 5.88 | 5.70 | 6.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 28.9% | 14.7% | ||
| Avg | - | 9.2% | 8.5% | ||
| Low | - | -8.2% | 1.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.